Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a common blood thinner help ventilated COVID-19 patients breathe easier?

NCT ID NCT04545541

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether giving nebulised heparin (a blood thinner delivered as a mist) to COVID-19 patients on mechanical ventilation could help them get off the breathing machine sooner and reduce deaths. The trial combined data from several smaller studies in Australia, Ireland, the US, and the UK, involving 57 adults in intensive care. Patients received either heparin or standard care/placebo for up to 10 days while on a ventilator.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nebulised heparin (a blood thinner given as a mist into the lungs)
What this could lead to
If it works, this could point toward a simple, low-cost treatment to help COVID-19 patients on ventilators recover faster and need less breathing support.
What could go wrong
This is a small, early-stage analysis of several trials, so results may not be definitive. Heparin can increase bleeding risk, especially in critically ill patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

57 people

The number who actually took part.

Started

Nov 2020

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Currently in an intensive care unit (ICU) or scheduled for transfer to the ICU. During the pandemic, critically ill inpatients might be cared for outside of the walls of the usual physical environment of ICU. For this reason, ICU is defined as an area designated for inpatient care of the critically ill where therapies including invasive mechanical ventilation can be provided. * Endotracheal tube in place * Intubated yesterday or today * PaO2 to FIO2 ratio less than or equal to 300 while intubated * Acute opacities not fully explained by effusions, lobar/lung collapse and nodules, affecting at least one lung quadrant on chest X-ray or CT * The acute opacities on chest X-ray or CT are most likely due to COVID-19 * There is a PCR positive sample for SARS-CoV-2 within the past 21 days or there are results pending or further testing is planned. The sample can be a nasal or pharyngeal swab, sputum, tracheal aspirate, bronchoalveolar lavage, or another sample from the patient. Exclusion Criteria: * Enrolled in another clinical trial that is unapproved for co-enrolment * Heparin allergy or heparin-induced thrombocytopaenia (HIT) * APTT \> 120 seconds and this is not due to anticoagulant therapy * Platelet count \< 20 x 109 per L * Pulmonary bleeding, which is frank bleeding in the trachea, bronchi or lungs with repeated haemoptysis or requiring repeated suctioning * Uncontrolled bleeding * Pregnant or might be pregnant. Females aged 18-49 years are excluded unless there is documented menopause or hysterectomy or a pregnancy test was performed and is negative. * Receiving or about to commence extracorporeal membrane oxygenation (ECMO) or high frequency oscillatory ventilation (HFOV) * Myopathy, spinal cord injury, or nerve injury or disease with a likely prolonged incapacity to breathe independently e.g. Guillain-Barre syndrome * Acute brain injury that may result in long-term disability * Usually receives home oxygen * Dependent on others for personal care due to physical or cognitive decline * Death is imminent or inevitable within 24 hours * The clinical team would not be able to set up the study nebuliser and ventilator circuit as required including with active humidification * Clinician objection * Refusal of participant (person responsible) consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Frederick Health Hospital

    Frederick, Maryland, 21701, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.